2 results
Approved WMORecruiting
The primary objective of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progressionfree survival (PFS) (by independent imaging…
Approved WMORecruiting
Evaluate the efficacy of nonavalent HPV vaccination in women with a CIN lesion who will undergo or have undergone a LEEP in preventing recurrent CIN II-III after 24 months.